SPHK1 and lymphopenia: This is of critical importance, for future drug development as some of better described SK1 inhibitors (e.g. FTY720) have profound side effects that may render them unusable in cancer patients (e.g. lymphopenia, bradycardia and liver function tests derangement) [37, 38].